Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)

Zymeworks Inc. : Jefferies Raises Target Price to $52 from $50

Zymeworks presents new clinical data on Phase 1 study of ZW191

Zymeworks - ZW191 Demonstrates Anti-Tumor Activity in Platinum-Resistant Ovarian Cancer Across FrΑ Expression Levels

Zymeworks - Median Duration of Response not Reached; Six-Month Pfs Rate of 61% in Both Groups

Zymeworks - ZW191 Achieves Corr of 64.5% at 6.4 Mg/Kg in High-Grade Serous Proc

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at Esmo Congress 2026

Zymeworks' ZW191 Shows 64.5% Response Rate at 6.4 Mg/kg in Phase 1 Ovarian Cancer Trial

Zymeworks price target raised to $52 from $50 at Jefferies

US Stocks on the MOVE-American Express, Gorman-Rupp, Moderna

Zymeworks Signs Global Licensing and Collaboration Deal with Roche for ZW209

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for Zw209, a Trispecific T Cell Engager Targeting Dll3

Zymeworks: Eligible to GET Tiered High-Single-Digit to Mid-Teen Royalties on Global Net Sales Protected by Patents Extending into 2040S

Zymeworks: Potential to GET up to $718 Mln in Additional Development, Commercial & Sales-Based Milestones Under Roche Deal

Zymeworks Licenses Experimental Lung Cancer Drug to Roche in up to $813 Million Deal

Zymeworks: to GET $55 Mln Upfront Payment & $40 Mln Payment upon Initiation of Phase 1B Trial

Zymeworks: Roche to Fund Phase 1a Trial & Have Exclusive Right to Develop & Commercialize ZW209 Globally

Zymeworks Names Suzanne Monahan Commercial SVP and Theravance Biopharma General Manager

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Zymeworks Publishes Update to Financial Calendar